Description_x000D_ Immunogen_x000D_ Human CtIP_x000D_ Application_x000D_ Suggested starting dilutions are as follows: ICC/IF: 1:100-1:1000, IP: Assay-dependent dilution, WB: 1:500-1:1000 (3% Milk/TBST overnight), ChIP assay: Assay-dependent dilution, PLA: Assay-dependent dilution. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user._x000D_ Physical form_x000D_ Phosphate-buffered saline, pH 7.4, containing no preservatives_x000D_ Disclaimer_x000D_ Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals._x000D_ Biochem/physiol Actions_x000D_ CtIP, a 125 kD protein, was originally found interacting with a transcription repressor, CtBP, through the PLDLS motif (CtBP-Interacting Protein) thus suggested a role in transcription. Studies have shown that CtIP also interacts with BRCA1 protein through the c-terminus BRCT domains also suggested that CtIP is a potential tumor suppressor. This CtIP-BRCA1 interaction can be disruppted by DNA damaging agents including UV or gamma-irradiation. Li et al (Nature 406, 210 - 215 (2000)) have shown that ATM phosphorylates CtIP at serine residues 664 and 745, and mutation of these sites abrogates the dissociation of BRCA1 from CtIP, resulting in persistent repression of BRCA1-dependent induction of GADD45 upon ionizing radiation._x000D_ Features and Benefits_x000D_ Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.